NYSE$THC

Tenet Healthcare Corp · Q4 2024 earnings

Q4 2024 earnings · · Before market open · Investor relations

Briefing

Tenet Healthcare Corporation reported a strong fourth quarter with net income rising to $318 million and adjusted diluted EPS reaching $3.44. Net operating revenue declined to $5.072 billion due to hospital divestitures, but strong ambulatory growth and favorable payer mix partially offset the impact. Adjusted EBITDA improved to $1.048 billion, with a margin of 20.7%.

Headline financials

Total Revenue

$5.07B

Previous: $5.38B-5.7%
EPS (adj)

$3.44

Previous: $2.42+42.3%
Same-facility NPSR Growth

8.6%

No prior period
Revenue per Case Growth

8.5%

No prior period
Surgical Cases Growth

0.1%

No prior period
Surgical Cases SBD Growth

-1.5%

No prior period
Admissions Growth

5.0%

No prior period
Outpatient Visits Growth

0.4%

No prior period
ER Visits Growth

-2.4%

No prior period
Hospital Surgeries Growth

0.2%

No prior period
Adjusted EBITDA Margin

20.7%

No prior period
Capital Expenditures

-$330M

Previous: -$208M-58.7%
Net Income

$318M

Previous: $456M-30.3%
Operating Income

$776M

Previous: $735M+5.6%
Gross Profit

$776M

Previous: $721M+7.6%

Revenue & EPS history

Tenet Healthcare · Revenue · Quarterly

$5.07B

Q4 2024-5.7%vs Q4 2023
Beat estimate in 9 of 13 quarters(69%)
ActualEstimate

Revenue by segment

Tenet Healthcare · $4.86B total across 2 segments · Q3 2023

  • Hospital Operations
    $3.92B+3.7%
  • Ambulatory Care
    $941M+16.7%

Forward guidance

Tenet Healthcare expects stable revenue growth in 2025, driven by strong ambulatory and same-hospital performance. Cost optimizations and favorable payer mix will support margin expansion.

Tailwinds

  • Expected 2025 revenue between $20.6B and $21.0B
  • Adjusted EBITDA projected between $3.975B and $4.175B
  • Ambulatory segment revenue expected to grow by 3-6%
  • Hospital admissions projected to rise by 2-3%
  • Continued strong free cash flow outlook for 2025

Headwinds

  • Revenue impact from divested hospitals
  • Potential pressures from rising labor costs
  • Margin pressures from increased outpatient services
  • Higher interest expenses affecting net income
  • Uncertainty around Medicaid reimbursement programs

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

-1.0%

Avg return

Earnings day

+1.0%

Avg return

5 days after

+3.0%

Avg return

30 days after

49%

33 / 68 earnings

Positive

+13.3%

Q3 2024

Best reaction

-31.1%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.7%+3.8%-2.8%
Q4 2025-0.7%+6.4%+29.3%
Q3 2025-5.3%-4.5%+0.6%
Q2 2025+0.3%+3.6%+12.2%
Q1 2025+0.2%-9.6%+7.4%
Q4 2024-9.1%-4.0%-11.6%
Q3 2024+13.3%+11.9%+1.8%
Q2 2024+8.0%+10.2%+18.6%
Q1 2024-0.7%-2.8%+6.8%
Q4 2023-0.0%+6.9%+14.0%
Q3 2023+1.1%+3.4%+26.8%
Q2 2023+3.3%+0.2%+5.4%
Q1 2023+1.5%+5.6%+27.3%
Q4 2022-3.2%+13.8%-3.3%
Q3 2022-31.1%-24.0%-17.2%
Q2 2022+7.8%+7.9%+7.9%
Q1 2022-0.3%-8.0%-16.6%
Q4 2021-5.3%+12.1%+23.0%
Q3 2021+9.3%+6.7%+20.2%
Q2 2021-0.7%+1.6%+3.0%
Q1 2021-3.7%-4.5%+11.5%
Q4 2020-5.1%-4.7%+6.3%
Q3 2020+0.9%+3.4%+12.9%
Q2 2020+0.6%+10.1%+10.6%
Q1 2020-8.6%+19.3%+34.4%
Q4 2019-14.5%-23.2%-47.4%
Q3 2019+8.6%+14.8%+30.4%
Q2 2019-3.8%-5.0%-7.9%
Q1 2019+3.2%+8.1%-24.1%
Q4 2018+11.5%+21.6%+16.5%
Q3 2018-9.3%-3.2%-8.7%
Q2 2018-15.6%-15.9%-17.4%
Q1 2018-4.4%+0.7%-1.3%
Q4 2017+7.7%+13.7%+23.6%
Q3 2017+7.7%+9.2%+4.6%
Q2 2017-14.8%-16.2%+2.3%
Q1 2017-4.1%-3.6%-13.8%
Q4 2016-12.2%-4.5%-18.5%
Q3 2016-5.6%-12.3%-24.8%
Q2 2016-9.9%-10.2%-21.9%
Q1 2016-0.1%
Q4 2015+5.4%
Q3 2015+9.2%
Q2 2015+2.1%
Q1 2015-3.2%
Q4 2014+1.0%
Q3 2014-5.3%
Q2 2014+4.8%
Q1 2014+1.7%
Q4 2013-6.3%
Q3 2013-6.8%
Q2 2013-7.0%
Q1 2013+0.9%
Q4 2012+3.5%
Q3 2012+5.4%
Q2 2012+11.8%
Q1 2012+1.1%
Q4 2011+0.0%
Q3 2011+4.9%
Q2 2011-4.6%
Q1 2010-6.3%
Q1 2011+1.6%
Q4 2008+3.0%
Q3 2009+0.0%
Q3 2010+0.0%
Q2 2009+0.7%
Q2 2010+0.7%
Q4 2009+0.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro